791. From Preclinical Evidence to Clinical Innovation: NanoBEO as first-in-class novel therapeutic for Neuropsychiatric symptoms and Pain in Severe Dementia
Abstract Background Dementia currently affects some 57.4 million people worldwide and approximately 99% of patients with Alzheimer’s Disease (AD) exhibit neuropsychiatric symptoms (NPS). Agitation is a particularly resistant clinical burden characterized by verbal and physical aggression that compromises safety. Author...